www.fdanews.com/articles/187353-amgen-leukemia-drug-gets-full-approval-in-eu
![Amgen](https://www.fdanews.com/ext/resources/test/Drug-Images4/Amgen_logo.jpg?t=1614976958&width=430)
Amgen Leukemia Drug Gets Full Approval in EU
June 25, 2018
European regulators cleared Amgen’s candidate for a rare form of leukemia nearly three years after its conditional approval.
The drug, Blincyto, is indicated for treatment of Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia. EU authorities granted it conditional approval in November 2015.
Regulators based the full authorization on a Phase 3 clinical trial. In the trial, Blincyto showed a superior improvement over standard of care chemotherapy.